Company Filing History:
Years Active: 2018
Title: Innovations of Mohamed E Bousmaqui
Introduction
Mohamed E Bousmaqui is a notable inventor based in Aul-Noy-lez-Valenciennes, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective NK-3 receptor antagonists. His work focuses on innovative compounds that have potential therapeutic applications.
Latest Patents
Bousmaqui holds a patent for "Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof." This invention relates to novel compounds of Formula I and their use in therapeutic treatments. It also includes a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. Additionally, the invention provides intermediates for the synthesis of compounds of Formula I.
Career Highlights
Bousmaqui is associated with Ogeda SA, where he continues to advance his research and development efforts. His work has been instrumental in exploring new avenues for treating disorders mediated by NK-3 receptors.
Collaborations
Some of his notable coworkers include Hamid R Hoveyda and Guillaume Dutheuil, who have collaborated with him on various projects.
Conclusion
Mohamed E Bousmaqui's innovative contributions to pharmaceutical science highlight his role as a key inventor in the field. His patent on selective NK-3 receptor antagonists showcases his commitment to advancing therapeutic solutions.